GLP-1R x GCGR x FGF21R

评价在重度高甘油三酯血症受试者中皮下注射DR10624治疗12周后降低TG的疗效、安全性和耐受性

DR10624 is an Fc fusion protein tri-agonist with balanced glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR)/ fibroblast growth factor 21 receptor (FGF21R) agonizing activities. The objectives of the planned clinical investigation will be to evaluate the efficacy of DR10624 on fasting serum triglyceride (TG) levels after 12 weeks of treatment in subjects with severe hypertriglyceridemia (SHTG).

在中国健康成人受试者、超重或肥胖受试者中评估DR10624单次皮下给药的安全性和耐受性。